Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Crohn's disease (CD) is a lifelong gastrointestinal inflammatory condition that often requires surgery, particularly for patients diagnosed in childhood. CD has been linked to a combination of microbial, genetic, and environmental factors, but pathogenesis remains unknown. We outline a framework for multicenter surgical biobanking across a large geographic area, required to enable meaningful research, and evaluate feasibility using the 2016 Consolidated Standards of Reporting Trials (CONSORT) extension to randomized pilot and feasibility trials. We also share proof-of-concept RNA sequencing and immunohistochemistry results demonstrating adequacy to generate high-quality translational results.
Methods: CD patients (5-17.2 years) scheduled for intestinal resection were included. Intra-abdominal sepsis was excluded. Surgeons from 10 Canadian children's hospitals underwent virtual training on tissue collection. Bowel, mesenteric fat, and lymph nodes were collected intraoperatively, fixed in formalin and RNAlater, and shipped overnight to a single lab. Feasibility was determined by protocol adherence, study recruitment efficacy, and tissue viability.
Results: Tissue has been collected from 18 patients at seven sites since the study launched in 2023. The biobank is on track to bank 30-50 % of the total estimated eligible yearly case volume. Adherence to shipping protocols was impacted by the day of the week of the operation and by shipping office closures. Proof-of-concept immunohistochemistry demonstrated high-quality multiplex images. RNA sequencing identified 560 genes discriminating between inflamed and non-inflamed bowel.
Conclusions: Establishing a national biobank for surgically resected pediatric CD is feasible for translational investigations of CD pathogenesis. Preliminary experiments demonstrate functional protocols sufficient to collect research-quality tissue.
Level Of Evidence: Prognosis Study - Level IV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpedsurg.2025.162195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series.
Aliment Pharmacol Ther
July 2025
Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission.
View Article and Find Full Text PDFInflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomy.
Urol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.
Materials And Methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs.
Imperatorin alleviates intestinal fibrosis by suppressing AIM2-mediated GSDMD pyroptosis in macrophages.
Cell Mol Gastroenterol Hepatol
September 2025
Guangdong Provincial Key Laboratory of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address:
Background & Aims: Over-activation of pyroptosis, recently reidentified as Gasdermin D (GSDMD)-mediated proinflammatory cell death, results in severe inflammation-related disorders. Intestinal fibrosis, an inflammation-related disorder, remains one of the most common and intractable complications of Crohn's disease (CD). However, it is unknown whether excessive pyroptosis contributes to the development of intestinal fibrosis in CD.
View Article and Find Full Text PDFPrim-O-glucosylcimifugin attenuates intestinal fibrosis by modulating TGF-β/MAPK signaling and ECM remodeling.
Life Sci
September 2025
KM Convergence Research Division, Korea Institute of Oriental Medicine, Republic of Korea; Korean Convergence Medical Science Major, KIOM School, University of Science & Technology (UST), Daejeon, 34054, Republic of Korea. Electronic address:
Background: Intestinal fibrosis is a severe and progressive complication of inflammatory bowel disease (IBD), particularly Crohn's disease (CD), for which no effective anti-fibrotic therapies currently exist.
Purpose: This study aimed to investigate the anti-fibrotic efficacy and underlying mechanisms of Prim-O-glucosylcimifugin (POG), a natural chromone derivative, in TGF-β1-stimulated human intestinal fibroblasts.
Methods: Fibrosis was modeled in human intestinal fibroblast cell lines (CCD-18Co) and human primary intestinal myofibroblasts (HIMF) using TGF-β1.
Vedolizumab Achieves Pan-Enteric Mucosal Healing in Crohn's Disease: A Prospective Observational Study.
United European Gastroenterol J
September 2025
Sheba Medical Center Tel Hashomer, Faculty of Medical and Health Sciences, Gastroenterology Institute, Tel-Aviv University, Tel Aviv, Israel.
Background: Mucosal healing (MH) is a key treatment goal in Crohn's disease (CD). However, evidence on pan-enteric MH (PE-MH) in CD patients treated with vedolizumab remains limited. We aimed to assess vedolizumab efficacy in achieving PE-MH using PillCam Crohn's capsule.
View Article and Find Full Text PDF